Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midazolam + sufentanil + cisatracurium
- Development stage
- Unknown
- Lead developer
- Shaanxi Provincial People's Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
midazolam + sufentanil + cisatracurium is a pharmacological combination used for the induction of anesthesia, specifically as a standardized protocol in clinical research at Shaanxi Provincial People's Hospital. The regimen consists of midazolam, a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor to provide sedation and amnesia; sufentanil, a potent synthetic opioid analgesic that targets the mu-opioid receptor; and cisatracurium, a non-depolarizing neuromuscular blocking agent that antagonizes nicotinic acetylcholine receptors at the neuromuscular junction. This combination is designed to facilitate a stable transition to a surgical plane of anesthesia, particularly in elderly patients undergoing procedures such as hysteroscopy.
- Other names
- Anesthesia induction protocol (Shaanxi Provincial People's Hospital)
02
Targets
Nicotinic Acetylcholine ReceptorBZD site (GABA-A receptor benzodiazepine site)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on midazolam + sufentanil + cisatracurium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midazolam + sufentanil + cisatracurium.